PSEUDO-PHEOCHROMOCYTOMA AFTER MULTIPLE-DRUG INTERACTIONS INVOLVING THE SELECTIVE MONOAMINE-OXIDASE INHIBITOR SELEGILINE

被引:30
作者
LEFEBVRE, H
NOBLET, C
MORRE, N
WOLF, LM
机构
[1] CHU ROUEN, DEPT ENDOCRINOL, ROUEN, FRANCE
[2] CHU ROUEN, DEPT PHARMACOL, ROUEN, FRANCE
关键词
D O I
10.1111/j.1365-2265.1995.tb02604.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A patient presented with paroxysmal hypertension and typical clinical features of phaeochromocytoma, but with a normal adrenal computed tomographic scan and much higher plasma noradrenaline than adrenaline concentrations. Urinary vanillylmandelic acid concentrations were only moderately elevated. This syndrome probably arose as a consequence of an interaction between the monoamine oxidase inhibitor selegiline, the sympathomimetic agent ephedrine, and a tricyclic antidepressant. The mechanism of the interaction is thought to be related to increased sympathetic release of noradrenaline by ephedrine, inhibition of catabolism by selegiline, and inhibition of reuptake of noradrenaline by the tricyclic. Although newer selective monoamine oxidase inhibitors are considered to be safer than earlier non-selective inhibitors, they can also contribute to drug interactions mimicking phaeochromocytoma.
引用
收藏
页码:95 / 98
页数:4
相关论文
共 23 条
[1]  
Baldessarini RJ, 1990, PHARMACOL BASIS THER, P414
[2]   STEREOCHEMICAL ASPECTS OF MAO INTERACTIONS - REVERSIBLE AND SELECTIVE INHIBITORS OF MONOAMINE-OXIDASE [J].
BENEDETTI, MS ;
DOSTERT, P .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1985, 6 (06) :246-251
[3]  
BLACKWELL B, 1988, SIDE EFFECTS DRUGS A, V12, P8
[4]   AN UPDATE OF RECENT MOCLOBEMIDE INTERACTION DATA [J].
DINGEMANSE, J .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1993, 7 (3-4) :167-180
[5]   SUBSTRATE-SELECTIVE ACTIVATION OF RAT-LIVER MITOCHONDRIAL MONO-AMINE OXIDASE BY OXYGEN [J].
FOWLER, CJ ;
CALLINGHAM, BA .
BIOCHEMICAL PHARMACOLOGY, 1978, 27 (16) :1995-2000
[6]   MOCLOBEMIDE [J].
FREEMAN, H .
LANCET, 1993, 342 (8886-7) :1528-1532
[7]   DEPRENYL AS SYMPTOMATIC THERAPY IN PARKINSONS-DISEASE [J].
GOLBE, LI .
CLINICAL NEUROPHARMACOLOGY, 1988, 11 (05) :387-400
[8]   POTENTIAL FLUOXETINE SELEGILINE INTERACTION [J].
JERMAIN, DM ;
HUGHES, PL ;
FOLLENDER, AB .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (10) :1300-1300
[9]  
KEETON TK, 1980, PHARMACOL REV, V32, P81
[10]  
KNOLL J, 1978, BIOCHEM PHARMACOL, V27, P1739, DOI 10.1016/0006-2952(78)90550-6